초록 ▼

The invention concerns a recombinant adenylcyclase, comprising at least a polypeptide sequence including one or several cleavage site of at least a molecule with site-specific proteolytic activity, said polypeptide sequence being inserted in the catalytic domain of an adenylcyclase while preserving

The invention concerns a recombinant adenylcyclase, comprising at least a polypeptide sequence including one or several cleavage site of at least a molecule with site-specific proteolytic activity, said polypeptide sequence being inserted in the catalytic domain of an adenylcyclase while preserving its enzymatic activity. The invention also concerns methods for screening molecules with proteolytic activity using said recombinant adenylcyclase.

대표청구항 ▼

1. A recombinant adenyl cyclase, characterized in that it comprises at least one polypeptide sequence including one or more cleavage sites for at least one molecule with site-specific proteolytic activity, said polypeptide sequence being inserted into the catalytic domain of an adenyl cyclase while

1. A recombinant adenyl cyclase, characterized in that it comprises at least one polypeptide sequence including one or more cleavage sites for at least one molecule with site-specific proteolytic activity, said polypeptide sequence being inserted into the catalytic domain of an adenyl cyclase while at the same time conserving the enzymatic activity thereof. 2. The adenyl cyclase as claimed in claim 1, characterized in that the inserted polypeptide sequence also comprises a polypeptide sequence corresponding to a molecule with proteolytic activity. 3. The adenyl cyclase as claimed in either of claims1 and2, characterized in that the inserted polypeptide sequence contains at least one cleavage site specific for the HIV protease. 4. The adenyl cyclase as claimed in claim 3, characterized in that the cleavage site specific for the HIV protease is the p5 site, comprising the series of amino acids corresponding to SEQ ID NO 1. 5. The adenyl cyclase as claimed in claim 3, characterized in that the inserted polypeptide sequence contains the HIV protease bordered by the p5 and p6 cleavage sequences corresponding to the sequence SEQ ID NO 3. 6. The adenyl cyclase as claimed in one of claims 1 to 5, characterized in that the adenyl cyclase is the adenyl cyclase of 7. The adenyl cyclase as claimed in claim 6, characterized in that the polypeptide sequence is inserted between amino acids 224 and 225 of the sequence SEQ ID NO 4. 8. A polynucleotide, characterized in that it encodes an adenyl cyclase as claimed in any one of claims 1 to 7. 9. A vector, characterized in that it contains a polynucleotide as claimed in claim 8, or in that it is capable of expressing an adenyl cyclase as claimed in any one of claims 1 to 7. 10. The vector as claimed in claim 9, capable of expressing an adenyl cyclase as claimed in claim 4, characterized in that it is the vector pKACp5 deposited on Jan. 4, 2000, with the CNCM under the item number I-2378. 11. The vector as claimed in claim 9, capable of expressing an adenyl cyclase as claimed in claim 5, characterized in that it is the vector pKACPr deposited on Jan. 4, 2000, with the CNCM under the item number I-2377. 12. A method for detecting the proteolytic activity of a molecule, characterized in that it comprises the steps consisting in:a. complementing a bacterial or fungal strain or a cell line deficient in endogenous adenyl cyclase with a recombinant adenyl cyclase as claimed in any one of claims 1 to 7, said bacterial or fungal strain or cell line having a phenotype the expression of which is linked to the enzymatic activity of the adenyl cyclase; b. bringing said molecule to be tested into contac t with said complemented strain or line; c. culturing said strain or line under conditions for demonstrating the phenotype linked to the activity of the adenyl cyclase; d. monitoring the expression of said phenotype. 13. The method as claimed in claim 12, characterized in that the bacterial or fungal strain or cell line deficient in endogenous adenyl cyclase is complemented by introduction of a polynucleotide as claimed in claim 8, or of a vector as claimed in one of claims 9 to 11. 14. The method as claimed in either of claims12 and13, characterized in that the bacterial strain deficient in endogenous adenyl cyclase is 15. The method as claimed in one of claims 12 to 14, characterized in that the phenotype the expression of which is linked to the enzymatic activity of the adenyl cyclase is the ability to ferment lactose or maltose. 16. The method as claimed in one of claims 12 to 14, characterized in that the phenotype the expression of which is linked to the enzymatic activity of the adenyl cyclase is the ability to be resistant to an antibiotic. 17. The method as claimed in one of claims 12 to 14, characterized in that the phenotype the expression of which is linked to the enzymatic activity of the adenyl cyclase is the ability to express a readily detectable protein, in particular luciferase or GFP. 18. A method for detecting the resistance of a molecule with proteolytic activity, to an inhibitor, characterized in that it comprises the steps of a method as claimed in any one of claims 12 to 17, and in that it also comprises bringing said molecule into contact with said inhibitor in step b. 19. The method as claimed in claim 18, characterized in that the level of said resistance is also measured by quantifying the expression of the phenotype studied. 20. The method as claimed in either of claims18 and19, characterized in that said molecule with proteolytic activity is the HIV protease. 21. A diagnostic kit for detecting molecules with proteolytic activity, characterized in that it contains:a. a bacterial or fungal strain or a cell line deficient in endogenous adenyl cyclase, b. a DNA fragment, a purified polynucleotide or a vector encoding a recombinant adenyl cyclase, into the catalytic site of which are inserted one or more cleavage site(s) corresponding to the molecule with proteolytic activity. 22. A diagnostic kit for detecting molecules with proteolytic activity, characterized in that it contains:a. a bacterial or fungal strain or a cell line deficient in endogenous adenyl cyclase, b. a DNA fragment, a purified polynucleotide or a vector encoding an adenyl cyclase, in a configuration such that it is possible t o insert the gene encoding the proteolytic molecule of interest, optionally flanked by auto-proteolytic sequences, into the catalytic domain of the adenyl cyclase while at the same time conserving the enzymatic activity thereof, c. specific primers for amplifying the DNA encoding the proteolytic molecule of interest, optionally flanked by auto-proteolytic sequences, in order to insert it into the DNA fragment of b. 23. The use of an adenyl cyclase as claimed in any one of claims 1 to 7, of a polynucleotide as claimed in claim 8, or of a vector as claimed in one of claims 9 to 11, for producing a diagnostic kit for detecting the activity of molecules with proteolytic activity or their resistance to an inhibitor, these molecules being encoded by viruses present in the serum or the cells of a patient. 24. The use of an adenyl cyclase as claimed in any one of claims 1 to 7, of a polynucleotide as claimed in claim 8, or of a vector as claimed in one of claims 9 to 11, for producing a diagnostic kit for quantifying the (molecules with proteolytic activity resistant to an inhibitor/molecules with proteolytic activity not resistant to said inhibitor) ratio in a patient, said molecules with proteolytic activity being present in the serum or the cells of said patient. 25. The use as claimed in either of claims23 and24, characterized in that the molecule with proteolytic activity is the HIV protease. 26. A method for identifying molecules with site-specific proteolytic activity, in a library of molecules, characterized in that a method as claimed in one of claims 12 to 17 is carried out on the various molecules of the library, the adenyl cyclase complementing the bacterial strain comprising the specific target amino acid sequence for which the possible molecules with proteolytic activity are being sought. 27. A method for identifying the target sequences for a molecule with proteolytic activity, characterized in that a method as claimed in one of claims 12 to 17 is carried out on a library of bacterial or fungal strains or cell lines, each one being complemented with an adenyl cyclase as claimed in one of claims 1 to 7 comprising a different amino acid sequence in order to determine whether this sequence consists of a cleavage site for said molecule with proteolytic activity. 28. Anbacterial strain deficient in endogenous adenyl cyclase, characterized in that it is the DHT1 strain deposited on Jan. 4, 2000, with the CNCM under the item number I-2375, or a mutant of this strain. 29. A vector encoding the HIV protease, characterized in that it is the vector pUCVIH deposited on Jan. 4, 2000, with the CNCM under the item number I-2376.